• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
lutein
Bamboo Leaf Extract
TZ-SN01 Prefilled Single-nozzle Nasal Spray Device
TZ-YN01 Prefilled Double-nozzle Nasal Spray Device
TZ-50/100AE Airless Drug Delivery Systems (Airless Container)
TPF 14 Topical Liquid Medicinal Bottle Set

Zydus Cadila gets USFDA nod to market midodrine hydrochloride tablets

expresspharmaSeptember 04, 2020

Tag: Zydus Cadila , Midodrine Hydrochloride Tablets , FDA

Zydus Cadila received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Sanofi, GSK initiate Phase 1/2 clinical trial of COVID-19 vaccine candidate

Next:Dr Reddy’s Labs launch methylphenidate hydrochloride extended-release tablets USP in US

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Zydus Cadila gets USFDA nod to market midodrine hydrochloride tablets | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
HFHA(m-6FDAP)

HFHA(m-6FDAP)
Deltamine (FDA)

Deltamine (FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Ifosfamide (FDA)

Ifosfamide (FDA)
Tacrolimus (FDA)

Tacrolimus (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service